Emerald Mutual Fund Advisers Trust lifted its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 9.9% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 429,302 shares of the biopharmaceutical company's stock after purchasing an additional 38,778 shares during the quarter. Ultragenyx Pharmaceutical comprises about 1.2% of Emerald Mutual Fund Advisers Trust's portfolio, making the stock its 27th biggest position. Emerald Mutual Fund Advisers Trust owned approximately 0.52% of Ultragenyx Pharmaceutical worth $23,848,000 at the end of the most recent quarter.
Other institutional investors have also recently made changes to their positions in the company. Headlands Technologies LLC acquired a new stake in shares of Ultragenyx Pharmaceutical in the 1st quarter worth $28,000. nVerses Capital LLC acquired a new stake in shares of Ultragenyx Pharmaceutical in the 2nd quarter worth $33,000. UMB Bank n.a. boosted its position in shares of Ultragenyx Pharmaceutical by 58.1% in the 2nd quarter. UMB Bank n.a. now owns 958 shares of the biopharmaceutical company's stock worth $39,000 after purchasing an additional 352 shares in the last quarter. Values First Advisors Inc. purchased a new position in Ultragenyx Pharmaceutical in the 3rd quarter worth $56,000. Finally, Allspring Global Investments Holdings LLC raised its stake in Ultragenyx Pharmaceutical by 67.7% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 3,318 shares of the biopharmaceutical company's stock worth $155,000 after acquiring an additional 1,339 shares during the last quarter. Institutional investors and hedge funds own 97.67% of the company's stock.
In related news, CFO Howard Horn sold 7,465 shares of Ultragenyx Pharmaceutical stock in a transaction dated Thursday, October 10th. The stock was sold at an average price of $52.76, for a total value of $393,853.40. Following the sale, the chief financial officer now directly owns 92,301 shares in the company, valued at approximately $4,869,800.76. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other Ultragenyx Pharmaceutical news, CEO Emil D. Kakkis sold 20,000 shares of the business's stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $55.85, for a total transaction of $1,117,000.00. Following the completion of the sale, the chief executive officer now directly owns 2,223,985 shares in the company, valued at approximately $124,209,562.25. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Howard Horn sold 7,465 shares of the business's stock in a transaction that occurred on Thursday, October 10th. The stock was sold at an average price of $52.76, for a total value of $393,853.40. Following the sale, the chief financial officer now owns 92,301 shares of the company's stock, valued at approximately $4,869,800.76. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 47,556 shares of company stock worth $2,519,367 in the last ninety days. Company insiders own 5.80% of the company's stock.
NASDAQ:RARE opened at $50.99 on Friday. Ultragenyx Pharmaceutical Inc. has a 52 week low of $34.06 and a 52 week high of $60.37. The stock has a market capitalization of $4.70 billion, a PE ratio of -6.98 and a beta of 0.58. The stock's 50-day moving average price is $55.70 and its 200-day moving average price is $47.94.
Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last posted its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($1.52) EPS for the quarter, beating analysts' consensus estimates of ($1.64) by $0.12. Ultragenyx Pharmaceutical had a negative return on equity of 266.02% and a negative net margin of 121.57%. The firm had revenue of $147.03 million for the quarter, compared to analysts' expectations of $123.20 million. During the same period last year, the firm earned ($2.25) EPS. The company's quarterly revenue was up 35.7% on a year-over-year basis. Sell-side analysts expect that Ultragenyx Pharmaceutical Inc. will post -6.29 earnings per share for the current fiscal year.
A number of equities analysts recently issued reports on the company. Wedbush raised their target price on Ultragenyx Pharmaceutical from $43.00 to $46.00 and gave the stock a "neutral" rating in a research note on Friday, August 2nd. Royal Bank of Canada restated an "outperform" rating and issued a $77.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Thursday, September 26th. Barclays reduced their target price on Ultragenyx Pharmaceutical from $83.00 to $81.00 and set an "overweight" rating for the company in a research note on Monday, August 5th. Wells Fargo & Company raised their target price on Ultragenyx Pharmaceutical from $72.00 to $75.00 and gave the stock an "overweight" rating in a research note on Friday, August 2nd. Finally, Canaccord Genuity Group restated a "buy" rating and issued a $111.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, July 23rd. Two research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $85.08.
View Our Latest Stock Report on RARE
Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Ultragenyx Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ultragenyx Pharmaceutical wasn't on the list.
While Ultragenyx Pharmaceutical currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.